FOLLOW US
Actual patient. Results may vary.
*Glow was reported by patients using a validated scale that included satisfaction with how radiant their skin looked.1
One treatment approved for all skin tones that smooths and hydrates cheeks to improve cheek skin smoothness.1
SKINVIVE® is injected as tiny, intradermal microdroplets of hyaluronic acid within the dermis, so patients won’t see any change in the shape or volume of their face—just healthier looking skin and a lasting glow.1,2*
SKINVIVE® is a hyaluronic acid gel that’s injected as intradermal microdroplets below the surface of the skin, increasing hydration to improve cheek smoothness. Patients treated with SKINVIVE® reported satisfaction with how glowing, hydrated, refreshed, and healthy their skin looked compared to baseline.1,4
Patients treated with SKINVIVE® showed a significant improvement in skin smoothness of the cheeks, with results lasting through month 6. The SKINVIVE® primary endpoint is at least a 1-point improvement in skin smoothness on both cheeks compared to baseline.1
58% of patients treated with SKINVIVE® had their fine lines improved by ≥1 grade on the Allergan Fine Lines Scale (AFLS) as early as month 1 with improvement lasting through month 6.1
Patients treated with SKINVIVE® saw significant improvement with how glowing, hydrated, refreshed, and healthy their skin looked.1*†
SKINVIVE®-treated patients showed a significant improvement in skin hydration of the cheeks compared to control, based on MoistureMeterD® measurements.1
*Lasts 6 months with optimal treatment. Glow was reported by patients using a validated scale that included satisfaction with how radiant their skin looked.1
†As measured using the Satisfaction with Skin module of the validated FACE-Q questionnaire.1
References: 1. SKINVIVE® by JUVÉDERM® Directions for Use, 2023. 2. de la Guardia C, Virno A, Musumeci M, Bernardin A, Silberberg MB. Rheologic and Physicochemical Characteristics of Hyaluronic Acid Fillers: Overview and Relationship to Product Performance. Facial Plast Surg. 2022;38(2):116-123. doi:10.1055/s-0041-1741560. 3. SKINVIVE® by JUVÉDERM® Press Release, May 2023. 4. SKINVIVE® by JUVÉDERM® Patient Labeling, 2023.
INDICATIONS
SKINVIVE by JUVÉDERM® injectable gel is indicated for intradermal injection to improve skin smoothness of the cheeks in adults over the age of 21.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
This product should not be used in patients who have severe allergies, marked by a history of anaphylaxis or history or presence of multiple severe allergies, and should not be used in patients with a history of allergies to Gram-positive bacterial proteins or lidocaine contained in this product.
WARNINGS
PRECAUTIONS
ADVERSE EVENTS
In clinical studies, injection site responses (ISRs) observed in >5% of treated subjects included redness, lumps/bumps, swelling, bruising, pain, tenderness, firmness, discoloration, and itching. Most ISRs were mild. Adverse events reported through postmarketing surveillance outside of the United States included inflammatory reaction, inflammatory nodule, unsatisfactory result, loss/lack of correction, allergic reaction, anxiety, vascular occlusion, infection, dry skin, increase/decrease in sensation, and abscess.
To report an adverse reaction with SKINVIVE by JUVÉDERM®, please call the Allergan® Product Support Department at 1-877-345-5372. Please see Directions for Use for more information.
SKINVIVE by JUVÉDERM® is available only by a licensed physician or properly licensed practitioner.
INDICATIONS
SKINVIVE by JUVÉDERM® injectable gel is indicated for intradermal injection to improve skin smoothness of the cheeks in adults over the age of 21.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
This product should not be used in patients who have severe allergies, marked by a history of anaphylaxis or history or presence of multiple severe allergies, and should not be used in patients with a history of allergies to Gram-positive bacterial proteins or lidocaine contained in this product.
WARNINGS
PRECAUTIONS
ADVERSE EVENTS
In clinical studies, injection site responses (ISRs) observed in >5% of treated subjects included redness, lumps/bumps, swelling, bruising, pain, tenderness, firmness, discoloration, and itching. Most ISRs were mild. Adverse events reported through postmarketing surveillance outside of the United States included inflammatory reaction, inflammatory nodule, unsatisfactory result, loss/lack of correction, allergic reaction, anxiety, vascular occlusion, infection, dry skin, increase/decrease in sensation, and abscess.
To report an adverse reaction with SKINVIVE by JUVÉDERM®, please call the Allergan® Product Support Department at 1-877-345-5372. Please see Directions for Use for more information.
SKINVIVE by JUVÉDERM® is available only by a licensed physician or properly licensed practitioner.